Katy Tsai, MD
@katyktsai
Followers
418
Following
193
Statuses
115
med onc | ucsf | melanoma center | for all those OUT LIVING | canadian transplant | these tweets are my own!
San Francisco, CA
Joined March 2015
RT @DrBetofMDPhD: Kicking off #WIM2024. Our biggest meeting ever. The most meaningful, rejuvenating meeting of the year which fosters profe…
0
3
0
RT @FunchainMD: What an honor to spend an afternoon with @EmensLeisha, @sitcancer president, discussing how women uniquely leverage network…
0
3
0
RT @FunchainMD: Cancer emotions are complex, human behavior in the face of existential stress is complex, so many layers to why patients ma…
0
3
0
RT @UCSFCancer: Today, 6/2 11:30am CT S406 | @ucsf's endocrinologist Zoe Quandt, MD, MS, gives a preview of her presentation “HLA associati…
0
2
0
💪🏼🎉 dream team!
Proud of this article published with @katyktsai and @drnehaggoyal outlining survivorship care for patients who had systemic therapy for melanoma- a growing field that needs much more research!
1
0
11
RT @GlitzaMDPhD: Excellent insights and tips on submitting your manuscript by @SaheliSadanand - and if you don’t have a real fireplace near…
0
4
0
RT @DrBetofMDPhD: 7th @AIMatMelanoma Women in Melanoma #WIM meeting. Absolutely my favorite meeting of the year- these women are such role…
0
5
0
RT @DrBetofMDPhD: Lifileucel cohorts 2+4 presented by Amod Sarnaik @MoffittNews. High disease burden, median 3 prior lines of therapy. All…
0
10
0
RT @drkomanduri: Great evening—dinner and an an escape room (though we failed 😞) with colleagues from @UCSF Divisions of Hematology/Oncol…
0
4
0
Got to share my journey a bit and look toward some future fun with @CardioOncology @UCSFCancer - thank you! 🙏🏼
Last week’s Grand Rounds with @katyktsai and @CardioOncology explored the emerging intersection of cardiology and cancer. Recording now available on YouTube.
1
1
5
RT @OmidHamidMD: Congrats @jasonlukemd Phase 3 KEYNOTE-716 KEYTRUDA, @Merck anti-PD-1, met primary endpoint (RFS) adjuvant high-risk stage…
0
16
0
RT @FunchainMD: Good morning 🌞 from the #WomenInMelanoma Best meeting of the year Making diversity happen at our institutions and our fiel…
0
5
0
New therapies always exciting (relatlimab!) but also v important to learn how to optimize ipi/nivo for efficacy/tox - ADAPT-IT @MPostow Checkmate-511 @CelesteLebbe
🚨 #ASCOtrainee spotlight: @VincentMaMD Survival outcomes associated with fewer combination Ipi/Nivo doses in advanced-stage #Melanoma How many doses of ICI do we need? More treatment doesn't always mean better outcomes, but ⬆️risk toxicity #ASCO21
0
0
2
@drdonsdizon @tmprowell @ASCO Absolutely a convo that seems to be forgotten with IO for unclear reasons. @SWOG S1404 with unique opportunity to look at this but now unfunded X2 despite committee support X3 and am hoping 3rd time the charm. Optimistic that I can help #melanoma lead way in IO but #survonc too!!
0
0
3
RT @SiwenONC: I had the opportunity to discuss two outstanding abstracts presented in the Melanoma Track @ASCO #ASCO21 @huntsmancancer http…
0
9
0
RT @FunchainMD: Historic #melanoma moment mOS of dacarbazine arm presented at #ASCO11: 9mo mOS of ipi/nivo 10 yrs later at #ASCO21: 72.1 m…
0
23
0
RT @HTawbi_MD: Fantastic delivery by @Liz_htx03 of our TRIDeNT results, grateful to my @MDAndersonNews colleagues for helping show that…
0
10
0
What we've all been waiting to hear... And administration advantage with both drugs given simultaneously rather than sequentially à la ipi/Nico... Congrats indeed
0
0
2